Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Convertible Debt (2023 - 2025)

Historic Convertible Debt for Mirum Pharmaceuticals (MIRM) over the last 3 years, with Q3 2025 value amounting to $309.4 million.

  • Mirum Pharmaceuticals' Convertible Debt rose 55.32% to $309.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $309.4 million, marking a year-over-year increase of 55.32%. This contributed to the annual value of $308.1 million for FY2024, which is 54.21% up from last year.
  • Mirum Pharmaceuticals' Convertible Debt amounted to $309.4 million in Q3 2025, which was up 55.32% from $308.9 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' 5-year Convertible Debt high stood at $309.4 million for Q3 2025, and its period low was $305.6 million during Q2 2023.
  • Over the past 3 years, Mirum Pharmaceuticals' median Convertible Debt value was $307.5 million (recorded in 2024), while the average stood at $307.5 million.
  • In the last 5 years, Mirum Pharmaceuticals' Convertible Debt soared by 53.37% in 2024 and then surged by 55.32% in 2025.
  • Mirum Pharmaceuticals' Convertible Debt (Quarter) stood at $306.4 million in 2023, then rose by 0.54% to $308.1 million in 2024, then rose by 0.42% to $309.4 million in 2025.
  • Its Convertible Debt was $309.4 million in Q3 2025, compared to $308.9 million in Q2 2025 and $308.5 million in Q1 2025.